Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and neurodegeneration.
Tango Therapeutics Inc. has disclosed the discovery of TNG-348, an orally active, potent, reversible allosteric inhibitor of the USP1 deubiquitinating enzyme.
Context Therapeutics Inc. has submitted an IND application to the FDA to begin a first-in-human phase I study of CTIM-76 in patients with claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
Investigators at Incyte Corp. have reported details on the discovery and preclinical characterization of new potent and selective inhibitors of cyclin-dependent kinase 2 (CDK2) as potential anticancer candidates.
Nutshell Biotech (Shanghai) Co. Ltd. has synthesized macrocyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Defence Therapeutics Inc. has announced the successful testing of a second-generation anticancer vaccine, ARM-002, using its lead anticancer molecule Accutox. When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002 led to an 80% complete response when combined with an anti-PD-1 immune-checkpoint inhibitor.
Valirx plc has signed an evaluation agreement with Imperial College London enabling Valirx to evaluate research relating to novel therapeutic candidates for cancer treatment.
Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
